Congress bans cosmetics animal testing, but FDA keeps emergency override power.

What it does

This bill prohibits cosmetic companies from conducting or contracting for animal testing in the U.S. starting one year after enactment, and bans the sale of cosmetics developed using animal testing. It also blocks the FDA from relying on new animal-test data to prove cosmetic safety unless no non-animal alternative exists and specific exemptions apply (foreign regulatory compliance, FDA-authorized testing for safety concerns, drug-cosmetic hybrids, or non-cosmetic regulatory testing). The bill preempts state cosmetics animal-testing laws, requiring them to match the federal standard.

Why we flagged it

The bill's operative mechanism is a prohibition on animal testing for cosmetics with narrow, safety-justified exemptions. It is fundamentally a consumer-protection and animal-welfare measure, not a deregulation or industry carve-out.

What the text implies

• The preemption clause (State authority section) eliminates state-level cosmetics animal-testing bans, centralizing authority in the FDA. States cannot impose stricter standards, even if constituents demand them—a federalism trade-off that may reduce local democratic input on animal welfare.
• The exemption for 'non-cosmetic purposes' (subsection 4) may allow animal testing on ingredients that are cosmetics-adjacent (e.g., sunscreen actives regulated as drugs) to proceed under different regulatory regimes, creating a potential loophole if companies reclassify products.

The full analysis lists 4 implications of this text.

Who stands to gain

cosmetics manufacturers using or developing non-animal testing methods; alternative testing technology providers (in vitro, computational modeling firms); cruelty-free cosmetics brands